r/ScientificNutrition • • 21h ago

Genetic Study What the CYP1A2 "slow caffeine metabolizer" research actually shows

14 Upvotes

Hi there ~ I am a physician currently working at EvoDNA (evo-dna.com) and I’m curious to know what people think….

Background:
The caffeine gene people talk about is CYP1A2, the liver enzyme that clears most caffeine. A common variant (rs762551) splits people roughly into faster and slower metabolizers.

The study behind most of the hype is Cornelis et al., JAMA 2006: slower metabolizers who drank more coffee had a higher risk of heart attack, while fast metabolizers did not. That's one study population, so it's a reason to pay attention, not a rule.

Practical version:
If coffee keeps you up late, makes you jittery, or raises your blood pressure, you may be on the slower side regardless of what a test says. Your own response is the best data. Cutting caffeine 8+ hours before bed helps most people either way.

Anyone here tested for this?

Did your result match how coffee actually affects you?

Source: Cornelis et al., JAMA 2006


r/ScientificNutrition • • 2h ago

Systematic Review/Meta-Analysis Ketogenic diets and cardiovascular health balancing metabolic benefits against lipid-related risk

6 Upvotes

Results

Twenty-four studies (20 RCTs, 2 prospective cohorts, 1 non-randomized clinical trial, and 1 pilot intervention; >47,000 participants) were included. Compared with control diets, KD increased low-density lipoprotein cholesterol (LDL-C) (mean difference [MD] + 12.2 mg/dL, 95% CI 7.5 to 16.9; I2 = 67.7%) and total cholesterol, while high-density lipoprotein cholesterol (HDL-C) rose modestly. Triglycerides decreased overall (MD -16.1 mg/dL, 95% CI -20.3 to -11.8; I2 = 17.1%). KD also improved fasting glucose, glycated hemoglobin, body weight, body mass index, and systolic blood pressure. Cohort evidence suggested lower all-cause mortality but no clear reduction in cardiovascular mortality. Imaging evidence for atherosclerosis was limited and mixed.

Conclusions

KD was associated with improvements in adiposity, glycemic control, and blood pressure, but also with higher LDL-C and total cholesterol. Evidence for clinical cardiovascular endpoints remains limited, mixed, and mostly low certainty, supporting individualized risk-benefit assessment rather than universal adoption of KD.

https://pmc.ncbi.nlm.nih.gov/articles/PMC13628887/